About The Study: In this disproportionality study of an adverse drug reaction database, researchers identified a disproportionality signal of suicidal ideation with semaglutide, but not for liraglutide, particularly among patients with co-reported antidepressant use, a proxy for affective disorders (a notable exclusion criteria of premarketing clinical trials). A detected signal of semaglutide-associated suicidal ideation warrants urgent clarification.
About The Study: In this disproportionality study of an adverse drug reaction database, researchers identified a disproportionality signal of suicidal ideation with semaglutide, but not for liraglutide, particularly among patients with co-reported antidepressant use, a proxy for affective disorders (a notable exclusion criteria of premarketing clinical trials). A detected signal of semaglutide-associated suicidal ideation warrants urgent clarification.
Corresponding Author: To contact the corresponding author, Georgios Schoretsanitis, MD, PhD, email george.schor@gmail.com.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jamanetworkopen.2024.23385)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
Journal
JAMA Network Open
Discover more from Science
Subscribe to get the latest posts sent to your email.
